Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

NCT07646613 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

COMBINATION_PRODUCT: ASY202
COMBINATION_PRODUCT: Placebo

Sponsor

Aspeya, Inc.